Compare Biogen Inc (BIIB) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Texas Instruments Incorporated — how do they compare? Biogen Inc trades at $195.5 (market cap $28.34B), while Texas Instruments Incorporated trades at $298.48 (market cap $278.08B). The key difference: Texas Instruments Incorporated is far larger — about 9.8× Biogen Inc's market cap, and Texas Instruments Incorporated pays a 1.86% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | TXN | |
|---|---|---|
Market Cap | $28.34B | $278.08B |
Sector | Health | Technology |
52-Week High | $216.63 | $332.35 |
52-Week Low | $122.68 | $153.33 |
Enterprise Value | $30.62B | $287.03B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Texas Instruments (TXN) trades at $298.57, down 4.15% over the past day, with technical indicators showing a bearish trend. The company reported mixed earnings, missing estimates in Q3 and Q4 2025 but beating in Q1 2026, with revenue of $17.68 billion in 2025. Analyst sentiment is positive, with a consensus price target of $317.20 and 48% buy ratings. Recent news highlights a CFO transition and strong AI-driven demand in data centers.
Outlook: TXN benefits from AI infrastructure growth and operational leverage, but faces risks from high valuation multiples and competitive pressures. The stock offers potential upside to the consensus target, supported by solid profitability and dividend payments, though investors should monitor debt levels and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
